Mycophenolate mofetil in treatment of childhood steroid-dependent nephrotic syndrome

##plugins.themes.academic_pro.article.sidebar##

Published Aug 19, 2016
Download
pdf
Vol. 94 No. 3 (2016): Issue Mar 2016

##plugins.themes.academic_pro.article.main##

Manel Jellouli
Sonia Fitouhi
Kamel Abidi
Yousra Hammi
Ouns Naija
Chokri Zarrouk
Tahar Gargah

Abstract

Abstract:
Objectives: To establish the efficacy of mycophenolate mofetil (MMF) in steroid dependent nephrotic syndrome and to determine the predictive factors for a good response.
Methods: retrospective hospital-based cohort study in the department of pediatric of Charles Nicolle hospital, between 2005 and 2012 included 30 children with steroid-dependent nephritic syndrome who were treated with MMF.
Results: A total of 30 patients (20 boys and 10 girls) were included. The mean age at the time of diagnosis was 5.45 years and treatment with MMF was performed at a mean age of 10.84 years. Side effects of steroid were found in 17 patients. Four patients had renal impairment (ciclotoxicity). The evolution of the disease was 5.45 years. The average rate of relapse was 1.75 relapses / year. The minimum dose of corticosteroids was 0.74 mg / kg / day. During MMF therapy, the average rate of relapse was 0.45 relapses / year (p<0.0001). The average residual steroid dose was 0.2 mg/kg/ day. Responding patients were younger at the onset of MMF (8.57 versus 12.83, p=0.009), had a short development period (3.75 vs 7.03 years, p=0.05), had not received cyclosporine (p=0.02).
Conclusion: MMF allows steroid sparing and reduces the number of relapse. It is more effective than the patients are young, with short disease outcome and had not previously been treated with cyclosporine.

Keywords:

nephrotic syndrome, corticosteroid, children, mycophenolate mofetil.

##plugins.themes.academic_pro.article.details##

References

  1. Niaudet P, Boyer O. Idiopathic nephrotic syndrome in childhood : clinical aspects. Pediatr Nephrol 2009: 667-702.
  2. Deschênes G, Leclerc A. Epidémiologie du syndrome néphrotique de l'enfant. Arch Pediatr 2010;17:622-3.
  3. Schachter AD. The pediatric nephrotic syndrome spectrum: clini¬cal homogeneity and molecular heterogeneity. Pediatr Transplant 2004; 8:344-8.
  4. Vivarelli M. Time for initial response to steroids is a major prognostic factor in idiopathic nephrotic syndrome. J Pediatr 2010; 156:965-71.
  5. Nakanishi K. Two-year outcome of the ISKDC regimen and frequent-relapsing risk in children with idiopathic nephrotic syndrome. Clin J Am Soc Nephrol 2013; 8:756-62.
  6. Iijima K, Sako M, Oba MS et al. Cyclosporine C2 monitoring for the treatment of frequently relapsing nephrotic syndrome in children: a multicenter randomized phase II trial. Clin J Am Soc Nephrol 2014; 9:271-8
  7. Kim J, Patnaik N, Chorny N et al. Second-line immunosuppressive treatment of childhood nephrotic syndrome: a single-center experience. Nephron Extra 2014; 4:8-17.
  8. Pravitsitthikul N, Willis NS, Hodson EM, Craig JC. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database Syst Rev 2013; 29:CD002290.
  9. Cammas B, Harambat J, Bertholet-Thomas A et al. Long-term effects of cyclophosphamide therapy in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. Nephrol Dial Transplant 2011; 26:178-184
  10. Gellermann J, Querfeld U. Frequently relapsing nephritic syndrome: treatment with mycophenolate mofetil. Pediatr Nephrol 2004; 19:101-4
  11. Zhang S, Audard V, Fan Q, Pawlak A, Lang P, Sahali D. Immunopathogenesis of idiopathic nephrotic syndrome. Contrib Nephrol 2011; 169:94-106
  12. Zhao W, Elie V, Baudouin V et al. Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome. Br J Clin Pharmacol 2010; 69:358-66.
  13. Saint-Marcoux F, Guigonis V, Decramer S et al. Development of a Bayesian estimator for the therapeutic drug monitoring of mycophenolate mofetil in children with idiopathic nephrotic syndrome. Pharmacol Res 2011; 63:423-31.
  14. Bérard E, Broyer M, Dehennault M et al. Corticosensitive nephrotic syndrome (or nephrosis) in children. Therapeutic guideline proposed by the Pediatric Society of Nephrology. Nephrol Ther 2005;1:150-6.
  15. Gellermann J, Querfeld U. Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil. Pediatr Nephrol 2004; 19:101-4.
  16. Afzal K, Bagga A, Menon S et al. Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome. Pediatr Nephrol 2007; 22:2059-65.
  17. Mendizábal S, Zamora I, Berbel O et al. Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome. Pediatr Nephrol 2005; 20:914-9.
  18. Banerjee S, Pahari A, Sengupta J, Patnaik SK. Outcome of severe steroid-dependent nephrotic syndrome treated with mycophenolate mofetil. Pediatr Nephrol 2013; 28:93-7.
  19. Baudouin V, Alberti C, Lapeyraque AL et al. Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial. Pediatr Nephrol 2012; 27:389-96.
  20. Bagga A, Hari P, Moudgil A, Jordan SC. Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. Am J Kidney Dis 2003; 42:1114-20.
  21. Novak I, Frank R, Vento S, Vergara M, Gauthier B, Trachtman H. Efficacy of mycophenolate mofetil in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol 2005; 20:1265-8.
  22. Hogg RJ, Fitzgibbons L, Bruick J al. Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol 2006; 1:1173-8
  23. Barletta GM, Smoyer WE, Bunchman TE et al. Use of mycophenolate mofetil in steroid-dependent and - resistant nephrotic syndrome. Pediatr Nephrol 2003; 18:833-837c
  24. Hodson EM, Alexander SI. Evaluation and management of steroid-sensitive nephrotic syndrome. Curr Opin Pediatr 2008; 20:145-50.
  25. Nickavar A, Safarzadeh AE, Sotoudeh K, Otukesh H, Hooman N. Mycophenolate mofetil for treatment of idiopathic nephrotic syndrome in children. Iran J Kidney Dis 2012; 6:346-9.
  26. Gellermann J, Weber L, Pape L et al. Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. J Am Soc Nephrol 2013; 24:1689-97.
  27. Ulinski T, Dubourg L, Saïd MH et al. Switch from cyclosporine A to mycophenolate mofetil in nephrotic children. Pediatr Nephrol 2005; 20:482-5.